PEAK6 Investments’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-17,300
Closed -$1.86M 3522
2024
Q2
$1.86M Buy
17,300
+1,000
+6% +$100K ﹤0.01% 1417
2024
Q1
$1.55M Buy
16,300
+12,800
+366% +$1.1M ﹤0.01% 1633
2023
Q4
$323K Sell
3,500
-34,000
-91% -$2.2M ﹤0.01% 2917
2023
Q3
$1.88M Buy
37,500
+11,100
+42% +$593K 0.01% 1370
2023
Q2
$1.67M Buy
+26,400
New +$1.44M 0.01% 1320
2022
Q3
Sell
-26,400
Closed -$1.67M 5023
2022
Q2
$1.67M Buy
+26,400
New +$1.55M ﹤0.01% 2524

Other funds holding BPMC

PEAK6 Investments's BPMC Position: Q3 2024 in Review

PEAK6 Investments opened a new position in Blueprint Medicines (BPMC) in Q3 2024: 20,893 shares worth $1.93M. The stake represents ﹤0.01% of the portfolio and ranks #1531 among its holdings. This is a return to the name: PEAK6 Investments previously reported a position in BPMC as recently as Q1 2024.

PEAK6 Investments first reported a position in BPMC in Q1 2023 and has held it in 5 quarters since. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • PEAK6 Investments held 20,893 shares of Blueprint Medicines worth $1.93M as of Q3 2024.
  • Blueprint Medicines was a new PEAK6 Investments position in Q3 2024.
  • Blueprint Medicines made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #1531 holding.
  • PEAK6 Investments first reported a position in Blueprint Medicines in Q1 2023 and has held it in 5 quarters since.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.